Spyre Therapeutics (SYRE) Total Current Liabilities (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Total Current Liabilities came in at $85.2 million in Q1 2026, up 20.49% YoY from $70.7 million in Q1 2025, and up 45.12% on a QoQ basis from $58.7 million in Q4 2025.
Spyre Therapeutics (SYRE) Total Current Liabilities (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Total Current Liabilities data on file, last reported at $85.2 million in Q1 2026.
- Quarterly Total Current Liabilities rose 20.49% year-over-year to $85.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.2 million (up 20.49% YoY) and the FY2025 annual result came in at $58.7 million, up 8.56% from the prior year.
- Total Current Liabilities rose to $85.2 million in Q1 2026, from $58.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $232.2 million in Q2 2023 to a low of $12.6 million in Q1 2023.
- A 5-year average of $53.3 million and a median of $44.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 1364.09% — and 2024, when it slumped 90.47%.
- Tracing SYRE's Total Current Liabilities over 5 years: stood at $14.7 million in 2022, then jumped by 118.19% to $32.0 million in 2023, then jumped by 69.05% to $54.1 million in 2024, then gained by 8.56% to $58.7 million in 2025, then soared by 45.12% to $85.2 million in 2026.
- The last three Total Current Liabilities figures came in at $85.2 million (Q1 2026), $58.7 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 63.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.30 Mn |
| Mar 31, 2026 | 85.16 Mn |
| Dec 31, 2025 | 58.69 Mn |
| Sep 30, 2025 | 46.27 Mn |
| Jun 30, 2025 | 83.06 Mn |
| Mar 31, 2025 | 70.68 Mn |
| Dec 31, 2024 | 54.06 Mn |
| Sep 30, 2024 | 57.54 Mn |
| Jun 30, 2024 | 22.12 Mn |
| Mar 31, 2024 | 42.82 Mn |
| Dec 31, 2023 | 31.98 Mn |
| Sep 30, 2023 | 44.87 Mn |
| Jun 30, 2023 | 232.23 Mn |
| Mar 31, 2023 | 12.64 Mn |
| Dec 31, 2022 | 14.66 Mn |
| Sep 30, 2022 | 17.68 Mn |
| Jun 30, 2022 | 15.86 Mn |
| Mar 31, 2022 | 16.30 Mn |
| Dec 31, 2021 | 20.14 Mn |
| Sep 30, 2021 | 20.43 Mn |